Managing drug shortages during a pandemic: tocilizumab and COVID-19

Amol A Verma; Menaka Pai; Sudipta Saha; Sally Bean; Michael Fralick; Jennifer L Gibson; Rebecca A Greenberg; Janice L Kwan; Lauren Lapointe-Shaw; Terence Tang; Andrew M Morris; Fahad Razak

doi:10.1503/cmaj.210531

Managing drug shortages during a pandemic: tocilizumab and COVID-19

CMAJ. 2021 May 25;193(21):E771-E776. doi: 10.1503/cmaj.210531. Epub 2021 May 5.

Affiliations

¹ Li Ka Shing Knowledge Institute (Verma, Saha, Razak), St. Michael's Hospital, Unity Health Toronto; Department of Medicine (Verma, Fralick, Kwan, Lapointe-Shaw, Tang, Morris, Razak); Institute of Health Policy, Management and Evaluation (Verma, Gibson, Razak); Dalla Lana School of Public Health (Bean, Gibson); Joint Centre for Bioethics (Bean, Gibson); and Department of Paediatrics (Greenberg), University of Toronto; Sunnybrook Health Sciences Centre (Bean); Sinai Health System (Fralick, Greenberg, Kwan, Morris); Department of Medicine (Lapointe-Shaw), and Toronto General Hospital Research Institute (Lapointe-Shaw), University Health Network; Women's Institute for Health System Solutions and Virtual Care (Lapointe-Shaw), Women's College Hospital; ICES Central (Lapointe-Shaw); Institute for Better Health (Tang), Trillium Health Partners; Division of Infectious Diseases (Morris), Sinai Health System and University Health Network, Toronto, Ont.; Department of Medicine (Pai), McMaster University; Hamilton Regional Laboratory Medicine Program (Pai); Hamilton Health Sciences (Pai), Hamilton, Ont. amol.verma@mail.utoronto.ca.
² Li Ka Shing Knowledge Institute (Verma, Saha, Razak), St. Michael's Hospital, Unity Health Toronto; Department of Medicine (Verma, Fralick, Kwan, Lapointe-Shaw, Tang, Morris, Razak); Institute of Health Policy, Management and Evaluation (Verma, Gibson, Razak); Dalla Lana School of Public Health (Bean, Gibson); Joint Centre for Bioethics (Bean, Gibson); and Department of Paediatrics (Greenberg), University of Toronto; Sunnybrook Health Sciences Centre (Bean); Sinai Health System (Fralick, Greenberg, Kwan, Morris); Department of Medicine (Lapointe-Shaw), and Toronto General Hospital Research Institute (Lapointe-Shaw), University Health Network; Women's Institute for Health System Solutions and Virtual Care (Lapointe-Shaw), Women's College Hospital; ICES Central (Lapointe-Shaw); Institute for Better Health (Tang), Trillium Health Partners; Division of Infectious Diseases (Morris), Sinai Health System and University Health Network, Toronto, Ont.; Department of Medicine (Pai), McMaster University; Hamilton Regional Laboratory Medicine Program (Pai); Hamilton Health Sciences (Pai), Hamilton, Ont.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use*
Antiviral Agents / therapeutic use*
COVID-19 / diagnosis
COVID-19 / mortality
COVID-19 / therapy
COVID-19 Drug Treatment*
Critical Care / methods
Drug Industry / organization & administration*
Female
Health Care Rationing / methods*
Health Care Rationing / organization & administration
Health Resources / supply & distribution*
Health Services Accessibility / organization & administration*
Humans
Male
Middle Aged
Ontario / epidemiology
Pandemics
Respiration, Artificial
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antiviral Agents
tocilizumab